Ana de la Torre Selected Research

montanide ISA 51

1/2016	Superior Efficacy and Safety of a Nonemulsive Variant of the NGcGM3/VSSP Vaccine in Advanced Breast Cancer Patients.
9/2010	Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ana de la Torre Research Topics

Disease

5	Neoplasms (Cancer) 01/2017 - 02/2007
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2016 - 12/2007
3	Breast Neoplasms (Breast Cancer) 01/2016 - 09/2010
1	Melanoma (Melanoma, Malignant) 01/2012
1	Neoplasm Metastasis (Metastasis) 09/2010
1	Fever (Fevers) 09/2010
1	Chills 09/2010
1	Injection Site Reaction 09/2010
1	Arthralgia (Joint Pain) 09/2010
1	Carcinoma (Carcinomatosis) 02/2007
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 02/2007

Drug/Important Bio-Agent (IBA)

9	VaccinesIBA 01/2017 - 02/2007
5	GangliosidesIBA 01/2016 - 02/2007
4	AntigensIBA 01/2017 - 02/2007
3	Epidermal Growth Factor (EGF)IBA 01/2016 - 02/2008
3	Cancer VaccinesIBA 09/2010 - 02/2008
2	montanide ISA 51IBA 01/2016 - 09/2010
2	proteoliposomesIBA 01/2016 - 01/2012
2	AntibodiesIBA 02/2008 - 02/2007
2	Sulfoglycosphingolipids (Sulfatides)IBA 12/2007 - 02/2007
2	Monoclonal AntibodiesIBA 12/2007 - 02/2007
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2017
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2016
1	CIMAvax EGFIBA 01/2016
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2012
1	Biological ProductsIBA 09/2010
1	ErbB Receptors (EGF Receptor)IBA 02/2008

Therapy/Procedure

1	Therapeutics 01/2016
1	Immunotherapy 01/2012
1	Subcutaneous Injections 01/2012